XORTX Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XRTX research report →
About the company
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD).
- CEO
- Allen Warren Davidoff
- IPO
- 2021
- Employees
- 2
- HQ
- Vancouver, BC, CA
Price Chart
- Market Cap
- $576.47K
- P/E
- -0.19
- P/S
- 0.00
- P/B
- 2.23
- EV/EBITDA
- -0.12
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -135.33%
- ROIC
- -238.89%
- Revenue
- $0 · 0.00%
- Net Income
- $-2,656,304 · 15.79%
- EPS
- $-14.20 · 48.27%
- Op Income
- $-3,313,012
- FCF YoY
- 19.56%
- 52W High
- $7.05
- 52W Low
- $1.73
- 50D MA
- $2.39
- 200D MA
- $2.77
- Beta
- 0.17
- Avg Volume
- 1.26M
Get TickerSpark's AI analysis on XRTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our XRTX coverage
Recent articles, reports, and earnings notes.
No research on XRTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XRTX report →Similar companies
Peers in the same neighborhood.